Efficacy of remdesivir in COVID-19 patients with a simulated two-arm controlled study

https://doi.org/10.1101/2020.05.02.20088559

Findings from simulated two arm study suggests that Remdesivir treatment results in a 33% significantly higher odds of discharge, a 29% significantly lower risk of death, and a 39% significantly lower risk for the combined endpoint of severe status and death. The median time to discharge for the remdesivir treated group was around half of the median time-to-discharge compared with the control arm. Remdesivir is effective in treating COVID-19 patients in terms of enhancing recovery and accelerating discharge.

Tags: